Astellas mycamine
WebJan 24, 2024 · Astellas reported Mycamine sales of $135 million for the year ending Mar 31, 2024. Shares of Novartis have gained 7.7% in the past year compared with the industry’s increase of 15.5%. Zacks... WebJan 24, 2024 · Astellas reported Mycamine ® sales of JPY 18.9 billion (USD 135 million) for the year ending March 31, 2024. The announcement comes after Sandoz successfully …
Astellas mycamine
Did you know?
WebDec 15, 2014 · PHILADELPHIA – Pharmaceutical company Astellas Pharma US, Inc., will pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promoting of the drug Mycamine for pediatric use. The settlement was announced today by United States Attorney Zane David Memeger and the Justice … WebMycamine is indicated for: Treatment of Invasive Candidiasis. Treatment of Esophageal Candidiasis. Prevention of Candida and Aspergillus infections in patients undergoing …
Webeffectiveness of MYCAMINE in patients younger than four months of age have not been established. The overall safety of MYCAMINE was assessed in 479 patients, ages three days through 16 years, who received at least one dose of MYCAMINE in 11 separate clinical trials. The mean treatment duration was 24.8 days. WebJan 24, 2024 · Astellas reported Mycamine sales of $135 million for the year ending Mar 31, 2024. Shares of Novartis have gained 7.7% in the past year compared with the …
WebMYCAMINE is contraindicated in persons with known hypersensitivity to micafungin sodium, any component of MYCAMINE, or other echinocandins. (4) WARNINGS AND PRECAUTIONS • • • • • ADVERSE REACTIONS • • To report SUSPECTED ADVERSE REACTIONS, contact Astellas Pharma US, Inc. at 1-800-727-7003 or FDA at 1-800-FDA … WebMar 31, 2024 · Mycamine is indicated for: Adults, adolescents ≥ 16 years of age and elderly treatment of invasive candidiasis; treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate;
WebJan 23, 2024 · MYCAMINE ® (Generic Name: micafungin sodium/product name in Japan: FUNGUARD ®) Sales of the product JPY 18.9 billion (fiscal year ended March 31, 2024) …
WebJan 24, 2024 · Astellas reported Mycamine ® sales of JPY 18.9 billion (USD 135 million) for the year ending March 31, 2024. The announcement comes after Sandoz successfully completed the acquisition of GSK’s global cephalosporins portfolio in October 2024. cody passmanWebJan 1, 2024 · Background: Liver tumours observed in rats exposed to micafungin led to a black box warning upon approval in Europe in 2008. Micafungin's risk for liver … calvin johnson ga tech jerseyWebJan 28, 2024 · FDA Approved: Yes (First approved March 16, 2005) Brand name: Mycamine. Generic name: micafungin sodium. Dosage form: for Injection. Company: Astellas Pharma US, Inc. Treatment for: Esophageal Candidiasis, Fungal Infection Prophylaxis, Candidemia. Mycamine (micafungin sodium) is an echinocandin antifungal … cody pate timpson texasWebJan 24, 2024 · Astellas reported Mycamine ® sales of JPY 18.9 billion (USD 135 million) for the year ending March 31, 2024. The announcement comes after Sandoz successfully … calvin johnson double teamedWeb• The efficacy of Micafungin for Injection against infections caused by fungi other than : Candida : has not been established. Additional pediatric use information is approved for Astellas Pharma US, Inc.’s Mycamine (micafungin for injection). However, due to Astellas Pharma US., Inc.’s marketing exclusivity rights, this drug product is ... cody party supplyWebAstellas Pharma US, Inc. announced today the launch and availability of their newest systemic anti-fungal agent MYCAMINE™ (micafungin sodium) for Injection to hospitals nationwide. The U.S. Food... calvin johnson football cardsWebMar 31, 2024 · Astellas reported Mycamine sales of US$135 million for the year ending March 31, 2024. Mycamine is indicated for treatment of invasive candidiasis and espophageal candidiasis, which are currently ... calvin johnson draft profile